vTv Therapeutics Reports $0 Revenue and Increased Losses in Q3 2025

vTv Therapeutics Inc. reported its financial results for the third quarter of 2025, revealing a continued lack of revenue generation, with total revenue remaining at $0 for both the three and nine months ended September 30, 2025. This marks a significant decline from the $1 million in revenue recorded during the same period in 2024, which was attributed to a milestone payment from a licensing agreement. The company’s operating expenses increased to $10.7 million for the third quarter, up from $6.5 million in the prior year, driven primarily by a 117.7% rise in research and development costs, which reached $7 million, reflecting heightened spending on clinical studies and drug manufacturing.

The company’s net loss attributable to common shareholders for the third quarter was $8.7 million, compared to a loss of $4.8 million in the same quarter of 2024. For the nine months ended September 30, 2025, the net loss attributable to common shareholders totaled $19.8 million, an increase from $14.8 million in the prior year. The increase in losses is largely due to escalated research and development expenses, which rose by 49.8% to $14 million, as the company continues to invest in its lead product candidate, cadisegliatin, which is currently in a Phase 3 trial for type 1 diabetes.

In terms of financial position, vTv Therapeutics reported cash and cash equivalents of $98.5 million as of September 30, 2025, a substantial increase from $36.7 million at the end of 2024. This increase was primarily due to a successful private placement that raised approximately $80 million in August 2025. The company’s total assets also rose to $99.5 million, compared to $38.3 million at the end of the previous fiscal year. The total liabilities increased to $28.9 million, up from $24 million, reflecting higher accounts payable and accrued expenses.

Operationally, vTv Therapeutics has made significant strides in its clinical development pipeline, particularly with cadisegliatin, which has received Breakthrough Therapy designation from the FDA. The company is also preparing to initiate a Phase 2 trial in the Middle East for type 2 diabetes patients. However, the company has faced challenges, including a clinical hold on the cadisegliatin program that was lifted in March 2025, allowing the company to proceed with its clinical trials.

Looking ahead, vTv Therapeutics anticipates continued investment in its research and development activities, particularly for cadisegliatin, and is exploring various financing strategies to support its operations. The company has indicated that it may need additional capital to fund ongoing clinical trials and operational expenses, emphasizing the uncertainty surrounding future revenue generation and the need for sustained financial support.